Kyntra Bio (KYNB) Non Operating Income (2015 - 2026)
Kyntra Bio (KYNB) posted Non Operating Income of $1.1 million for Q1 2026, down 92.19% sequentially from $14.2 million in Q4 2025, and up 169.49% YoY from $413000.0 in Q1 2025.
Kyntra Bio (KYNB) Non Operating Income (2015 - 2026) Analysis & Trends
Kyntra Bio has reported Non Operating Income for 12 years, with the latest figure at $1.1 million in Q1 2026.
- Quarterly Non Operating Income rose 169.49% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (up 392.71% YoY) and the FY2025 annual result came in at $2.9 million, down 44.43% from the prior year.
- Non Operating Income declined to $1.1 million in Q1 2026 per KYNB's latest filing, from $14.2 million in the prior quarter.
- Over five years, Non Operating Income peaked at $14.2 million in Q4 2025 and troughed at -$7.7 million in Q3 2025.
- A 5-year average of $1.3 million and a median of $688000.0 in 2024 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1970.35% in 2025, down 625.48% in 2025.
- Over 5 years, Non Operating Income stood at -$195000.0 in 2022, then sank by 100.0% to -$390000.0 in 2023, then surged by 276.41% to $688000.0 in 2024, then surged by 1970.35% to $14.2 million in 2025, then plunged by 92.19% to $1.1 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.1 million, $14.2 million, and -$7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 975,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.55 Mn |
| Mar 31, 2026 | 1.11 Mn |
| Dec 31, 2025 | 14.24 Mn |
| Sep 30, 2025 | -7.74 Mn |
| Jun 30, 2025 | 286,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 688,000.00 |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | -968,000.00 |
| Mar 31, 2024 | 2.24 Mn |
| Dec 31, 2023 | -390,000.00 |
| Sep 30, 2023 | 4.30 Mn |
| Jun 30, 2023 | -417,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | -195,000.00 |
| Sep 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 5.30 Mn |
| Mar 31, 2022 | -419,000.00 |
| Dec 31, 2021 | 2.01 Mn |
| Sep 30, 2021 | -1.30 Mn |